成人和儿童急性早幼粒细胞白血病患者应用三氧化二砷的对比研究

目的:探讨持续慢点三氧化二砷(As2O3)治疗儿童和成人急性早幼粒细胞白血病(APL)患者的疗效。方法:选取2007-2011年来我院就诊并采取持续慢点As2O3方式治疗的APL患者60例,其中儿童28例,成人32例。成人As2O3剂量为0.16 mg/kg,儿童为0.08 mg/kg,每分钟8滴,18-21 h完成,28天为一疗程。测量两组不同时间点的血总砷及血三价砷浓度,并记录治疗过程中高白细胞血症的发生率及高白细胞血症持续时间。结果:儿童中高白细胞血症的发生率为60.71%(17/28),明显高于成人的34.38%(11/32),差异有统计学意义(P0.05)。成人高白细胞血症平均持续时间为7.4天(6-10天),明显高于儿童的5.53天(4-8天),差异有统计学意义(P0.01)。成人不同时间点血总砷浓度高于儿童(P0.01),同一时间点血三价砷浓度高于儿童;随着用药时间延长,成人和儿童血总砷浓度和三价砷浓度增加,差异有统计学意义(均P0.01),于用药第14天达稳态。结论:儿童高白细胞血症发生率高于成人,持续时间短,血总砷及三价砷浓度水平低于成人。     

急性早幼粒细胞白血病维甲酸耐药性的双向电泳分析

目的:研究急性早幼粒细胞白血病(APL)对全反式维甲酸(ATRA)治疗敏感和耐药患者的外周血淋巴细胞在蛋白质组水平上的差异。方法:采用双向凝胶电泳(2-DE)对敏感和耐药患者的外周血淋巴细胞进行蛋白质组差异分析。结果:ATRA敏感和耐药患者外周血淋巴细胞的2-DE平均蛋白质点分别为(746±57)和(617±41),敏感与耐药患者的2-DE相比,有16个蛋白点表达明显上调,22个明显下调。另有4个蛋白点(Mr/pI:24.6kD/8.05,32.3kD/5.17,22.3kD/6.51,25.1kD/7.09)在敏感患者中特异表达,5个蛋白点(Mr/pI:21.9kD/5.45,23.4kD/6.27,22.9kD/6.65,23.9kD/7.39,24.7kD/7.65)在耐药患者中特异表达。结论:结果提示这些差异表达的蛋白质可能与APL对ATRA耐药的机制有关,该研究有助于揭示APL对ATRA耐药机理和发现新的临床分子标志物。     

急性早幼粒细胞白血病巩固治疗现状及进展

急性早幼粒细胞白血病(APL)曾被认为是最迅速的致命白血病,特点为临床表现凶险,早期死亡率高,治愈率低。药物全反式维甲酸及亚砷酸的应用,使APL的治疗取得了很大成功,其完全缓解率可达90%。然而APL的复发率仍然较高,约15%-30%。降低复发率和提高长期生存已成为研究重点,如何选择合理的缓解后治疗策略至关重要。缓解后治疗一般包括巩固治疗和维持治疗,而最佳治疗方案的确定仍然有待商榷。因此,本文就APL缓解后巩固治疗回顾相关文献进行整合分析,综述APL巩固治疗的研究进展。     

自噬与急性早幼粒细胞白血病

急性早幼粒细胞白血病(APL)是急性髓性白血病的一种亚型,其分子特征是具有t(15;17)(q22;q21)染色体易位,并形成融合肿瘤蛋白,进而阻止早幼粒细胞分化成熟。全反式维甲酸(ATRA)和三氧化二砷(ATO)作为经典的治疗APL的药物,能够通过转录调节并激活泛素-蛋白酶体通路,促进融合肿瘤蛋白降解,发挥其临床抗白血病的功效。最近的研究发现,ATRA与ATO均能够诱导APL细胞自噬,且自噬在融合肿瘤蛋白降解及诱导早幼粒细胞分化中发挥至关重要的作用。我们简要综述近年来APL的研究进展及自噬在APL治疗中的作用。     

更正声明

本刊2012年2月出版的第7卷第1期"病例报告"栏目中《急性早幼粒细胞白血病患者小孢根霉变种感染1例》一文中,第33页关键词"毛霉病,皮肤"更正为"毛霉病;皮肤"。第35页图题第2行"根霉菌在     

红色毛癣菌和枝孢样枝孢霉混合感染导致银屑病患者甲真菌病1例

目的报道1例银屑病患者出现红色毛癣菌和枝孢样枝孢霉混合感染导致的甲真菌病。方法报告病例,对甲标本进行真菌镜检和培养,对病原菌进行形态学及分子生物学鉴定。结果该病例经临床、真菌镜检和真菌培养鉴定,确诊为红色毛癣菌和枝孢样枝孢霉导致的甲真菌病。病原菌通过菌落和显微镜下形态特征结合rRNA内转录间隔区序列分析证实。结论通过形态学及分子生物学鉴定,证实为真菌红色毛癣菌和枝孢样枝孢霉混合感染导致的甲真菌病。     

全反式维甲酸对急性早幼粒细胞白血病患者血清学的影响

目的：探讨全反式维甲酸（All trans retinoic acid,ATRA）作为辅助剂在急性早幼粒细胞白血病（Acute promyelocytic leukemia, APL）治疗中,对患者血清促红细胞生成素（Erythropoietin,EPO）、血清铁蛋白、叶酸和维生素B12水平的影响。方法：回顾性分析 我院2011 年6 月-2015 年6 月接诊的50 例急性早幼粒细胞白血病患者的临床资料。根据患者的治疗方法不同将患者分为两组, A 组（亚砷酸钠治疗组）和B 组（亚砷酸钠联合ATRA）。对比两组患者治疗后血清铁蛋白、EPO、叶酸和维生素B12 恢复情况。结 果：两组患者入院时所有血清EPO、铁蛋白等比较,差异无统计学意义（P>0.05）;治疗后两组患者血清各指标均有所改善（P<0. 05）;治疗后B 组患者中EPO、血清B12、血清铁蛋白和叶酸恢复正常水平者明显多于A 组,差异具有统计学意义（P<0.05）。结论： 全反式维甲酸辅助治疗急性早幼粒细胞白血病患者能够更好的改善患者血清EPO、铁蛋白、叶酸和维生素B12 的异常,对于疾病 的治疗有一定的效果。     

多变根毛霉致面部皮肤毛霉病1例

报道1例由多变根毛霉引起的面部皮肤毛霉病.患者男,65岁,面部结节斑块伴痒半年余.皮损组织病理检查示真皮中下层有炎细胞及多核巨细胞浸润,并见粗大较短的无隔菌丝.经真菌培养和分子生物学鉴定,菌种鉴定为多变根毛霉.皮损经短时两性霉素B治疗后好转.     

急性淋巴细胞白血病患者侵袭性头状地霉感染1例及文献回顾

目的:通过报道1例急性淋巴细胞白血病患者侵袭性头状地霉感染的临床资料,并结合文献探讨头状地霉感染的临床特点、有效的诊断及治疗方法。方法:报道国内首例急性淋巴细胞白血病患者化疗后骨髓抑制期感染头状地霉病例,并对该病的诊断及治疗等进行系统文献回顾。结果:该白血病患者经血培养证实为头状地霉感染,并累及肺脏、肝脏和皮肤,治疗过程中先后采用卡泊芬净、脂质体两性霉素B和脂质体两性霉素B联合伏立康唑等治疗,虽然脂质体两性霉素B联合伏立康唑治疗患者体温正常,临床症状稍有改善,但是患者在化疗后40天放弃治疗并死于心肺功能衰竭。结论:头状地霉感染的发病率低,临床症状不够典型,诊断困难,预后差。根据患者的临床表现,结合血培养、GM实验、G实验和CT扫描等检查,可有助于诊断。头状地霉感染尚无非常有效的治疗方式,采用脂质体两性霉素B或两性霉素B联合伏立康唑或其他新的抗真菌药物可能获得一定的疗效,早期诊断、早期联合治疗和患者早期脱离粒缺状态是治疗成功的关键。     

持续缓慢静脉输注三氧化二砷治疗急性早幼粒细胞白血病的临床护理效应

目的:观察持续缓慢输注三氧化二砷(As_2O_3)治疗急性早幼粒细胞白血病(APL)病人的临床护理效应。方法:对196例急性早幼粒细胞白血病患者(APL)给予持续缓慢静脉输注As_2O_3治疗,每例患者As_2O_3日治疗总量按0.16mg/kg计算,As_2O_3注射液10毫克(10 mg/支),加入5%葡萄糖500毫升(或生理盐水500毫升)静脉滴注,8-10滴/分钟,每次滴注约18-21小时,连续用药28-50天,至完全缓解(CR)。同时,注重心理护理,加强输液管理,在用药过程中严密观察药物的毒副作用和对不良反应的及时对症护理等措施。结果:177例病人完全缓解(CR),完全缓解率达90.3%。结论:应用持续缓慢静脉输注As_2O_3治疗APL,实施积极有效的护理措施是取得显著疗效的重要环节。     

Myeloid sarcoma of the tongue as a first manifestation of acute promyelocytic leukemia: A case report

IntroductionWe describe a 35-year-old male patient showing a myeloid sarcoma (MS) of the tongue as the first manifestation of acute promyelocytic leukemia (APL). The MS can appear in all parts of the human body, but it is extremely rare in the tongue.Clinical caseThe main symptoms were a pain in the tongue, asthenia, gingivorrhagia, fever. We found a tumor in the tongue, which was irregular in size and located in the posterior region of the right lateral edge of the tongue. The diagnosis of MS was made by the anatomopathological and immunohistochemical study, while the definite diagnosis of APL was confirmed by the molecular test. The treatment of APL was based on the administration of trans-retinoic acid 45 mg/m² daily continuously and daunorubicin 60 mg/m² every other day for 4 doses, with a favorable therapeutic response to APL and MS.ConclusionPromyelocytic myeloid cells can infiltrate many organs extramedullary, such as the tongue, and this might precede bone marrow infiltration. The early identification of myeloid sarcoma allows to carry out an early treatment of the APL.     

Interplay of protein misfolding pathway and unfolded-protein response in acute promyelocytic leukemia

Protein misfolding has traditionally been linked to the pathogenesis of various neurodegenerative diseases. However, emerging evidence from various laboratories, including ours, suggests that protein misfolding may also play a fundamental role in some malignancies, particularly those caused by fusion oncoprotein generated from chromosomal translocation. Promyelocytic leukemia (PML) fused to the retinoic acid receptor (RAR) is a fusion oncoprotein linked to the transformation of acute promyelocytic leukemia (APL), and is not only a misfolded protein itself, but also promotes misfolding of nuclear receptor corepressor (N-CoR) protein, a corepressor essential for the growth-suppressive function of several tumor-suppressor proteins. PML–RAR promotes misfolding of N-CoR by inducing aberrant post-translational modification, which destabilizes its core and promotes instability. Misfolded N-CoR, thus, contributes to differentiation arrest and survival of APL cells through loss-of-function and aberrant gain-of-function properties. Therapeutic restoration of N-CoR conformation and function with conformation-modifying agents not only releases this differentiation arrest but also sensitizes APL cells to programmed cell death. These findings illustrate the potential of the misfolded N-CoR protein as a conformation-based drugable molecular target for APL, and highlights the promise of various conformation-modifying agents as novel therapeutics for APL. Protein conformational rearrangement, resulting from an inherited or acquired genetic alteration, could be a common pathological phenomenon contributing to transformation in different types of leukemias and solid tumors and, therefore, could serve as a common ground for designing a unifying diagnostic as well as therapeutic approach for a widely diverse disease such as cancer. To that end, APL could serve as a model for the development of a novel conformation-based therapeutic approach for other malignant diseases.     

Enhanced production of raw starch degrading enzyme using agro-industrial waste mixtures by thermotolerant Rhizopus microsporus for raw cassava chip saccharification in ethanol production

In the present study, solid-state fermentation for the production of raw starch degrading enzyme was investigated by thermotolerant Rhizopus microsporus TISTR 3531 using a combination of agro-industrial wastes as substrates. The obtained crude enzyme was applied for hydrolysis of raw cassava starch and chips at low temperature and subjected to nonsterile ethanol production using raw cassava chips. The agro-industrial waste ratio was optimized using a simplex axial mixture design. The results showed that the substrate mixture consisting of rice bran:corncob:cassava bagasse at 8?g:10?g:2?g yielded the highest enzyme production of 201.6?U/g dry solid. The optimized condition for solid-state fermentation was found as 65% initial moisture content, 35°C, initial pH of 6.0, and 5?×?10⁶ spores/mL inoculum, which gave the highest enzyme activity of 389.5?U/g dry solid. The enzyme showed high efficiency on saccharification of raw cassava starch and chips with synergistic activities of commercial α-amylase at 50°C, which promotes low-temperature bioethanol production. A high ethanol concentration of 102.2?g/L with 78% fermentation efficiency was achieved from modified simultaneous saccharification and fermentation using cofermentation of the enzymatic hydrolysate of 300?g raw cassava chips/L with cane molasses.     

Study of the mechanisms of crocetin-induced differentiation and apoptosis in human acute promyelocytic leukemia cells

Crocetin, the major carotenoid in saffron, exhibits potent anticancer effects. However, the antileukemic effects of crocetin are still unclear, especially in primary acute promyelocytic leukemia (APL) cells. In the current study, the potential antipromyelocytic leukemia activity of crocetin and the underlying molecular mechanisms were investigated. Crocetin (100 µM), like standard anti-APL drugs, all-trans retinoic acid (ATRA, 10 µM) and As₂O ₃ (arsenic trioxide, 50 µM), significantly inhibited proliferation and induced apoptosis in primary APL cells, as well as NB4 and HL60 cells. The effect was associated with the decreased expressions of prosurvival genes Akt and BCL2, the multidrug resistance (MDR) proteins, ABCB1 and ABCC1 and the inhibition of tyrosyl-DNA phosphodiesterase 1 (TDP1), while the expressions of proapoptotic genes CASP3, CASP9, and BAX/BCL2 ratio were significantly increased. In contrast, crocetin at relatively low concentration (10 µM), like ATRA (1 µM) and As ₂O ₃ (0.5 µM), induced differentiation of leukemic cells toward granulocytic pattern, and increased the number of differentiated cells expressing CD11b and CD14, while the number of the immature cells expressing CD34 or CD33 was decreased. Furthermore, crocetin suppressed the expression of clinical marker promyelocytic leukemia/retinoic acid receptor-α ( PML/RARα) in NB4 and primary APL cells, and reduced the expression of histone deacetylase 1 ( HDAC1) in all leukemic cells. The results suggested that crocetin can be considered as a candidate for future preclinical and clinical trials of complementary APL treatment.